Abstract
Anti-programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) monoclonal antibodies are commonly used for advanced non-squamous and squamous non-small cell lung cancer, preferably in patients with high PD-L1 expression (tumour proportion score [TPS] ≥50%) and no targetable driver mutations in epidermal growth factor receptor (EGFR), MET exon 14 skipping alterations, or gene fusions in ALK, ROS1, RET, and TRK.1 In the phase 3 KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival compared with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer patients with a TPS score of 50% or greater.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
